{
    "clinical_study": {
        "@rank": "11644", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin group", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastatin group"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo group"
            }
        ], 
        "brief_summary": {
            "textblock": "Periprocedural treatment with high-dose statins is known to have cardioprotective and\n      pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.\n\n      -Objective: to determine whether preoperative rosuvastatin loading is independently\n      associated with reduced myocardial ischemia and clinical outcomes in patients with stable\n      angina undergoing isolated off-pump coronary bypass (OPCAB) in patients with acute coronary\n      syndrome.\n\n      Study design\n\n        -  Prospective, double-blinded, single-center study of each 117 subjects enrolled\n\n        -  Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria\n           will be enrolled preoperatively.\n\n        -  Eligible subjects will be randomized 1:1 to A) High-dose rosuvastatin (n=117) vs. B)\n           Placebo (n=117).\n\n        -  The amount of preoperative administration of high-dose rosuvastatin will be 60mg of a\n           total\n\n        -  All subjects will undergo OPCAB procedure. - The primary and secondary endpoints will\n           be compared at 30 days and 2 years postoperatively between two groups"
        }, 
        "brief_title": "Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The presence of acute coronary syndrome,  including unstable angina, acute non-ST\n             elevation myocardial infarction\n\n          -  Age of 19 years or older\n\n          -  A need for isolated surgical myocardial revascularization\n\n          -  Patients with signed informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with combined surgery with coronary bypass grafting\n\n          -  On-pump conversion\n\n          -  Patients with any increase in liver enzymes\n\n          -  Patients with history of liver or muscle disease.\n\n          -  Patients with moderate renal dysfunction (creatinine>2.0mg/dl) or need for dialysis\n\n          -  Re-do surgery\n\n          -  Urgent/emergent surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "234", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971606", 
            "org_study_id": "4-2007-0253"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rosuvastatin group", 
                "Placebo group"
            ], 
            "description": "Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.\nA) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.\nB) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.", 
            "intervention_name": "Rosuvastatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Statin, coronary artery bypass grafting, off-pump surgery, acute coronary syndrome", 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Division of Cardiovascular Surgery, Severance Cardiovascular Hospital , Yonsei University College of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "other_outcome": [
            {
                "measure": "Incidence of postoperative atrial arrhythmia including atrial fibrillation and atrial flutter", 
                "safety_issue": "No", 
                "time_frame": "30 days after OPCAB"
            }, 
            {
                "measure": "Incidence of postoperative renal impairment or a need for dialysis", 
                "safety_issue": "No", 
                "time_frame": "30 days after OPCAB"
            }, 
            {
                "measure": "Late MACEs 2 years after OPCAB", 
                "safety_issue": "No", 
                "time_frame": "2 years after OPCAB"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Major adverse cardiac events (MACEs), which include the following: death from all causes, non-fatal myocardial infarction (MI), and repeat revascularization by percutaneous intervention or bypass surgery within 30 days after OPCAB.", 
            "measure": "Major adverse cardiac events (MACEs)", 
            "safety_issue": "No", 
            "time_frame": "30 days after OPCAB"
        }, 
        "reference": {
            "PMID": "17394957", 
            "citation": "Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007 Mar 27;49(12):1272-8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The degree of myocardial ischemia and inflammatory changes assessed by blood sampling and specific tests (CK-MB, Troponin T, ESR, CRP, hs-CRP) at the early period after OPCAB.", 
            "measure": "The degree of myocardial ischemia and inflammatory", 
            "safety_issue": "No", 
            "time_frame": "immediate, 24 hours, 48 hours, 72 hours, 7 days after OPCAB"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}